137 related articles for article (PubMed ID: 6980665)
21. dATP-mediated inhibition of DNA ligase by 2'-deoxycoformycin in T and B cell leukemia.
Lamballe F; Le Prise PY; Le Gall E; David JC
Leukemia; 1989 Feb; 3(2):97-103. PubMed ID: 2783473
[TBL] [Abstract][Full Text] [Related]
22. Dipyridamole enhancement of toxicity to L1210 cells by deoxyadenosine and deoxycoformycin combinations in vitro.
Kang GJ; Kimball AP
Cancer Res; 1984 Feb; 44(2):461-6. PubMed ID: 6362851
[TBL] [Abstract][Full Text] [Related]
23. In vitro and in vivo effect of deoxycoformycin in human T cell leukemia.
Yu AL; Kung FH; Bakay B; Nyhan WL
Adv Exp Med Biol; 1979; 122B():373-9. PubMed ID: 397762
[No Abstract] [Full Text] [Related]
24. Biochemical correlates of the differential sensitivity of subtypes of human leukemia to deoxyadenosine and deoxycoformycin.
Matsumoto SS; Yu AL; Bleeker LC; Bakay B; Kung FH; Nyhan WL
Blood; 1982 Nov; 60(5):1096-102. PubMed ID: 6289941
[TBL] [Abstract][Full Text] [Related]
25. Modulation of 9-beta-D-arabinofuranosyladenine 5'-triphosphate and deoxyadenosine triphosphate in leukemic cells by 2'-deoxycoformycin during therapy with 9-beta-D-arabinofuranosyladenine.
Plunkett W; Benjamin RS; Keating MJ; Freireich EJ
Cancer Res; 1982 May; 42(5):2092-6. PubMed ID: 6175407
[TBL] [Abstract][Full Text] [Related]
26. The biochemical and clinical consequences of 2'-deoxycoformycin in T cell chronic lymphocytic leukaemia.
Hallam LJ; Van der Weyden MB; Ackland SP; Bagnara AS; Whiteside MG
Scand J Haematol; 1984 Jan; 32(1):55-64. PubMed ID: 6607510
[TBL] [Abstract][Full Text] [Related]
27. 2'Deoxycoformycin and deoxyadenosine affect IL 2 production and IL 2 receptor expression of human T cells.
Ruers TJ; Buurman WA; van der Linden CJ
J Immunol; 1987 Jan; 138(1):116-22. PubMed ID: 3097141
[TBL] [Abstract][Full Text] [Related]
28. Human B lymphocytes and thymocytes but not peripheral blood mononuclear cells accumulate high dATP levels in conditions simulating ADA deficiency.
Goday A; Simmonds HA; Morris GS; Fairbanks LD
Biochem Pharmacol; 1985 Oct; 34(19):3561-9. PubMed ID: 3876835
[TBL] [Abstract][Full Text] [Related]
29. Synergistic effect of 3'-deoxyadenosine N1-oxide and adenosine deaminase inhibitors on growth of Ehrlich ascites tumor cells in vivo.
Svendsen KR; Overgaard-Hansen K; Frederiksen S
Cancer Chemother Pharmacol; 1988; 21(1):35-9. PubMed ID: 3257721
[TBL] [Abstract][Full Text] [Related]
30. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of RNA synthesis by deoxyadenosine plus deoxycoformycin in resting lymphocytes.
Matsumoto SS; Yu J; Yu AL
J Immunol; 1983 Dec; 131(6):2762-6. PubMed ID: 6196398
[TBL] [Abstract][Full Text] [Related]
32. Elimination of clonogenic malignant human T cells using monoclonal antibodies in combination with 2'-deoxycoformycin.
Schwartz CL; Minniti CP; Harwood P; Na S; Banquerigo ML; Strauss LC; Kurtzberg J; Smith SD; Civin CI
J Clin Oncol; 1987 Dec; 5(12):1900-11. PubMed ID: 3500279
[TBL] [Abstract][Full Text] [Related]
33. DNA repair in nondividing human lymphocytes: inhibition by deoxyadenosine.
Cohen A; Thompson E
Cancer Res; 1986 Apr; 46(4 Pt 1):1585-8. PubMed ID: 3485013
[TBL] [Abstract][Full Text] [Related]
34. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
[TBL] [Abstract][Full Text] [Related]
35. Mechanism of deoxyadenosine-induced catabolism of adenine ribonucleotides in adenosine deaminase-inhibited human T lymphoblastoid cells.
Bagnara AS; Hershfield MS
Proc Natl Acad Sci U S A; 1982 Apr; 79(8):2673-7. PubMed ID: 6283540
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of K and NK lymphocyte cytotoxicity by an inhibitor of adenosine deaminase and deoxyadenosine.
Grever MR; Siaw MF; Coleman MS; Whisler RL; Balcerzak SP
J Immunol; 1983 Jan; 130(1):365-9. PubMed ID: 6600187
[No Abstract] [Full Text] [Related]
37. Biochemical consequences of 2'-deoxycoformycin treatment in a patient with T-cell lymphoma. Some unusual findings.
de Korte D; Haverkort WA; van Leeuwen EF; Roos D; van Gennip AH
Cancer; 1987 Aug; 60(4):750-5. PubMed ID: 3496148
[TBL] [Abstract][Full Text] [Related]
38. Human monocytoid leukemia cells are highly sensitive to apoptosis induced by 2'-deoxycoformycin and 2'-deoxyadenosine: association with dATP-dependent activation of caspase-3.
Niitsu N; Yamaguchi Y; Umeda M; Honma Y
Blood; 1998 Nov; 92(9):3368-75. PubMed ID: 9787175
[TBL] [Abstract][Full Text] [Related]
39. The effect of deoxycoformycin on bone marrow cells treated with adenosine and deoxyadenosine and hemopoietic growth factors.
Fabian I; Williams Z
Hum Immunol; 1988 Feb; 21(2):81-7. PubMed ID: 3259223
[TBL] [Abstract][Full Text] [Related]
40. Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2'-deoxycoformycin.
Johnston JB; Lee K; Verburg L; Blondal J; Mowat MR; Israels LG; Begleiter A
Leuk Res; 1992 Aug; 16(8):781-8. PubMed ID: 1528066
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
